Immunological efficacy of heat shock protein 60 peptide DiaPep277™ therapy in clinical type I diabetes

Clinical and Experimental Immunology

Volumn 152, Issue 3, 2008, Pages 488-497

  Huurman, V A L ^a   Van Der Meide, P E ^b   Duinkerken, G ^a   Willemen, S ^a   Cohen, I R ^c   Elias, D ^d   Roep, B O ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d Develogen Ltd   (Israel)

Author keywords

Autoreactive T cell; C peptide; DiaPep277; hsp60; Immunotherapy; Intervention; Type 1 diabetes

Indexed keywords

C PEPTIDE; DIAPEP 277; GLUTAMATE DECARBOXYLASE; HEAT SHOCK PROTEIN 60; IMMUNOLOGIC AGENT; INTERLEUKIN 10; TETANUS TOXOID;

ARTICLE; AUTOIMMUNITY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; HEMATURIA; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE;

EID: 43349090939     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03656.x     Document Type: Article

References (32)

1. 1 Roep BO. The role of T‐cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia 2003 ; 46: 305–21.
2. 2 Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001 ; 358: 221–9.
3. 3 Lieberman SM, DiLorenzo TP. A comprehensive guide to antibody and T‐cell responses in type 1 diabetes. Tissue Antigens 2003 ; 62: 359–77.
4. 4 Di Lorenzo TP, Peakman M, Roep BO. Translational mini‐review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol 2007 ; 148: 1–16.
5. 5 Alizadeh BZ, Hanifi‐Moghaddam P, Eerligh P et al. Association of interferon‐gamma and interleukin 10 genotypes and serum levels with partial clinical remission in type 1 diabetes. Clin Exp Immunol 2006 ; 145: 480–4.
6. 6 Zehn D, Bevan MJ. T cells with low avidity for a tissue‐restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 2006 ; 25: 261–70.
7. 7 Hafler DA. Degeneracy, as opposed to specificity, in immunotherapy. J Clin Invest 2002 ; 109: 581–4.
8. 8 Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T‐cells from patients with type 1 diabetes. Diabetes 2005 ; 54: 92–9.
9. 9 Roep BO. T‐cell responses to autoantigens in IDDM. The search for the Holy Grail. Diabetes 1996 ; 45: 1147–56.
10. 10 Ludvigsson J, Heding L, Lieden G, Marner B, Lernmark A. Plasmapheresis in the initial treatment of insulin‐dependent diabetes mellitus in children. BMJ (Clin Res Ed) 1983 ; 286: 176–8.
11. 11 Eisenbarth GS, Srikanta S, Jackson R et al. Anti‐thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985 ; 2: 271–6.
12. 12 Bougneres PF, Landais P, Boisson C et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low‐dose cyclosporin. Diabetes 1990 ; 39: 1264–72.
13. 13 Staeva‐Vieira T, Peakman M, Von Herrath M. Translational mini‐review series on type 1 diabetes: immune‐based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007 ; 148: 17–31.
14. 14 Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3‐antibody therapy in new‐onset type 1 diabetes. N Engl J Medical 2005 ; 352: 2598–608.
15. 15 Herold KC, Hagopian W, Auger JA et al. Anti‐CD3 monoclonal antibody in new‐onset type 1 diabetes mellitus. N Engl J Med 2002 ; 346: 1692–8.
16. 16 Ablamunits V, Elias D, Reshef T, Cohen IR. Islet T cells secreting IFN‐gamma in NOD mouse diabetes: arrest by p277 peptide treatment. J Autoimmun 1998 ; 11: 73–81.
17. 17 Elias D, Cohen IR. Peptide therapy for diabetes in NOD mice. Lancet 1994 ; 343: 704–6.
18. 18 Elias D, Meilin A, Ablamunits V et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta‐cell antigens. Diabetes 1997 ; 46: 758–64.
19. 19 Cohen IR. Peptide therapy for Type I diabetes: the immunological homunculus and the rationale for vaccination. Diabetologia 2002 ; 45: 1468–74.
20. 20 Zanin‐Zhorov A, Cahalon L, Tal G, Margalit R, Lider O, Cohen IR. Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling. J Clin Invest 2006 ; 116: 2022–32.
21. 21 Huurman VA, Decochez K, Mathieu C, Cohen IR, Roep BO. Therapy with the hsp60 peptide DiaPep277 (trade mark) in C‐peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007 ; 23: 269–75.
22. 22 Schloot NC, Meierhoff G, Lengyel C et al. Effect of heat shock protein peptide DiaPep277 on ss‐cell function in paediatric and adult patients with recent‐onset diabetes mellitus type 1: two prospective, randomized, double‐blind phase II trials. Diabetes Metab Res Rev 2007 ; 23: 276–85.
23. 23 Raz I, Avron A, Tamir M et al. Treatment of new‐onset type 1 diabetes with peptide DiaPep277 (R) is safe and associated with preserved beta‐cell function: extension of a randomized, double‐blind, phase II trial. Diabetes Metab Res Rev 2007 ; 23: 292–8.
24. 24 Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta‐cell function in new‐onset type 1 diabetes and immunomodulation with a heat‐shock protein peptide (DiaPep277): a randomised, double‐blind, phase II trial. Lancet 2001 ; 358: 1749–53.
25. 25 Lohmann T, Leslie RD, Hawa M, Geysen M, Rodda S, Londei M. Immunodominant epitopes of glutamic acid decarboxylase 65 and 67 in insulin‐dependent diabetes mellitus. Lancet 1994 ; 343: 1607–8.
26. 26 Peakman M, Stevens EJ, Lohmann T et al. Naturally processed and presented epitopes of the islet cell autoantigen IA‐2 eluted from HLA‐DR4. J Clin Invest 1999 ; 104: 1449–57.
27. 27 Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent‐onset insulin‐dependent diabetes mellitus. N Engl J Med 1988 ; 319: 599–604.
28. 28 Arif S, Tree TI, Astill TP et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004 ; 113: 451–63.
29. 29 Schloot NC, Meierhoff G, Karlsson FM et al. Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the Third Immunology of Diabetes Society T‐Cell Workshop. J Autoimmun 2003 ; 21: 365–76.
30. 30 Van Halteren AG, Roep BO, Gregori S et al. Cross‐reactive mycobacterial and self hsp60 epitope recognition in I‐A(g7) expressing NOD, NOD‐asp and Biozzi AB/H mice. J Autoimmun 2002 ; 18: 139–47.
31. 31 Van De Linde P, Vd Boog PJ, Tysma OM et al. Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti‐interleukin‐2 receptor antibody versus anti‐thymocyte globulin. Clin Exp Immunol 2007 ; 149: 56–62.
32. 32 Huurman VA, Unger WW, Koeleman BP et al. Differential inhibition of autoreactive memory‐ and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y. Clin Exp Immunol 2007 ; 150: 487–93.